Alua completed her Bachelor and Master’s degrees at the University of Strasbourg, France, with both theses done on the Erasmus mobility program in the UK and Italy, respectively. During her Master thesis, she studied the regulation of the immune checkpoint receptor LILRB4/ILT3 in B-cell chronic lymphocytic leukemia. While waiting for her Canadian student visa, she also worked as a clinical researcher in Germany, studying immune spatial interactions on a single-cell level in cHBV liver.

Keen to explore epigenetic alterations upon UM171 treatment in HSC, she joined the team Sauvageau to start her Ph.D. in January 2024.